IP Verse

Neuroderm competitive analysis

Latest publications and patents of Neuroderm New

Explore the latest publications and patents granted to Neuroderm, showcasing their recent innovations and technological advancements.

Last updated on: Sep 27, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Neuroderm
EP2640358	Jan 3, 2018	Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same	No Opposition Filed Within Time Limit
EP2432454	Mar 1, 2017	Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors	Opposition Rejected

Latest patents of Neuroderm opposed by its competitors

Explore Neuroderm's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP2432454	Mar 1, 2017	Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors	1

Latest PTAB cases involving Neuroderm

Discover the latest PTAB cases involving Neuroderm, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 3, 2025

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Neuroderm
PGR2022-00040	May 12, 2022	NEURODERM	ABBVIE	Final Written Decision

Peer Comparison New

IP litigation analysis comparing Neuroderm with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced	Strategy Type
NEURODERM	-	1	1	-	Aggressive
ABBVIE	9	9	-	1	Aggressive
TEVA PHARMACEUTICALS	205	15	-	12	Highly Aggressive